• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Roche's Xolair reduces reactions to severe food allergies in study

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 25, 2024 at 05:52: PM
via Xolair, a 20-year-old asthma drug sold by Roche (ROG.S) and Novartis (NOVN.S) significantly reduced allergic reactions in people with multiple severe food allergies in a late-stage trial, researchers reported on Sunday at a medical meeting.

article source
 




Top Bottom
Back
Quote